Summary of patient characteristics and molecular analyses in AML secondary to MPD
| UPN . | Sex . | MPD . | AML . | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dx . | Age, y . | Nantes, %T . | Basel, %T . | Source . | Cytoreductive treatment . | Patient characteristics . | Unfractionated cell samples . | Purified cells . | |||||||||||||||||
| Granulocytic lineage . | Purified leukemic blasts . | T-cells . | |||||||||||||||||||||||
| FAB . | Age, y . | Delay, y . | Molecular and/or P cytogenetic abnormalities . | %Blasts . | source . | Nantes, %T . | Basel, %T . | source . | %T . | Source . | Method . | %T . | Source . | Method . | %T . | source . | Method . | ||||||||
| V617F-positive MPD/ V617F-negative AML | |||||||||||||||||||||||||
| NA-02 | F | PV | 70 | 79* | 94† | GRA/BM-CD15+ | Pipo | M2 | 72 | 2 | normal | 10 | BM smear | 0 | 0 | BMMC | 0 | PB-GRA | Ficoll | 0 | PB-CD34+ | FACS | 0 | PB-CD3+ | FACS |
| NA-32 | F | PV | 70 | 42 | 52 | PB GRA | Pipo | M1 | 72 | 2 | nd | 70 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| p128 | M | PV | 75 | nd | 30 | PB GRA | HU | M4 | 80 | 5 | Flt-3-ITD | 58 | PB smear | nd | 0 | PBMC | 0 | PB-CD15+ | MACS | 0 | PB-CD34+ | MACS | na | na | na |
| NA-01 | M | PV | 64 | 7 | 12 | BM smear | Pipo | M0 | 72 | 8 | nd | 91 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-03 | M | ET | 89 | 38 | 24 | PB GRA | HU | na | 91 | 2 | −Y | 42 | PB smear | 0 | 0 | PBMC | 0 | PB-GRA | Ficoll | 0 | PB-CD34+ | FACS | 0 | PB-CD3+ | FACS |
| BO-04 | F | ET | 52 | 21 | nd | PB GRA | None | M1 | 54 | 2 | t(10;16) | 93 | PB smear | 0 | 0 | PBMC | 0 | PB-GRA | Ficoll | na | na | na | na | na | na |
| DI-05 | M | ET | 69 | 12 | nd | BM smear | HU | M6 | 71 | 2 | complex, del(5q), +7, −Y | 52 | BM smear | 0 | 0 | BMMC | 0 | BM-CD15+ | FACS | 0 | BM-CD34+ | FACS | na | na | na |
| DI-35 | F | ET | 68 | 30 | 53 | BM smear | HU | M4 | 72 | 4 | complex, del(5q) | 45 | BM smear | 4 | 2 | BMMC | 0 | BM-CD15+ | FACS | 0 | PB/BM-CD34+ | FACS | 0 | PB/BM-CD3+ | FACS |
| NA-48 | M | IMF | 57 | 31 | 56 | BM smear | HU/Thal | M2 | 59 | 2 | complex, del(11q23) | 35 | BM smear | nd | 51 | BM smear | na | na | na | 0 | LC-blasts | LC | na | na | na |
| V617F-positive MPD/ V617F-positive AML | |||||||||||||||||||||||||
| NA-59 | M | PV | 64 | 46 | nd | PB GRA | HU/Pipo | na | 67 | 3 | nd | 15 | PB smear | 75 | nd | PBMC | 90 | PB-GRA | Ficoll | 85 | PB-CD34+ | FACS | 10 | PB-CD3+ | FACS |
| p185 | M | PV | 65 | nd | 30 | BM smear | HU | M2 | 83 | 18 | +8 | 75 | BM smear | nd | 69 | PB-CD34+ | 65 | PB-CD15+ | FACS | 69 | PB-CD34+ | FACS | na | na | na |
| NA-57 | F | ET | 47 | 82 | 89 | PB GRA‡ | HU | na | 60 | 13 | complex, del(20q), del(5q) | 15 | BM smear | 71 | 80 | PBMC | 78 | PB-GRA | Ficoll | 100 | PB-CD34+ | FACS | 0 | PB-CD3+ | FACS |
| DI-58 | F | ET | 64 | 26 | 34 | BM smear | na | M2 | 78 | 14 | complex, del(20q), −5, −7, +8 | 30 | BM smear | 41 | 66 | BMMC | 46 | PB-GRA | Ficoll | 56 | PB-CD34+ | FACS | 1 | PB-CD3+ | FACS |
| DI-60 | M | IMF | 71 | 75 | nd | BM smear | None | na | 74 | 3 | nd | 73 | PB smear | 80 | nd | PBMC | na | na | na | na | na | na | na | na | na |
| V617F-positive MPD/V617F-uninformative AML | |||||||||||||||||||||||||
| NA-30 | M | PV | 61 | 44 | nd | BM smear | 32P/Pipo | M2 | 68 | 7 | nd | 18 | BM smear | 43 | 67 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-33 | F | ET | 63 | 16 | nd | BM smear | HU/Pipo | M1 | 74 | 11 | nd | 91 | BM smear | 15 | nd | BM smear | na | na | na | na | na | na | na | na | na |
| NA-52 | M | IMF | 64 | 44 | 40 | BM smear | HU | M7 | 69 | 5 | nd | 24 | BM smear | nd | 59 | BM smear | na | na | na | na | na | na | na | na | na |
| V617F-negative MPD/V617F-negative AML | |||||||||||||||||||||||||
| NA-07 | M | PV | 53 | 0 | nd | BM smear | Pipo | M6 | 64 | 11 | nd | 75 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| NA-10 | M | ET | 67 | 0 | 0 | BM smear | HU | M4 | 74 | 7 | nd | 65 | PB smear | nd | 0 | PB smear | na | na | na | na | na | na | na | na | na |
| NA-11 | F | ET | 57 | 0 | 0 | BM smear | HU/32P/IFN/Ana | M2 | 73 | 16 | nd | 46 | PB smear | nd | 0 | PB smear | na | na | na | na | na | na | na | na | na |
| DI-12 | M | ET | 47 | 0 | nd | BM smear | HU | M7 | 49 | 2 | complex | 34 | BM smear | 0 | nd | BM smear | na | na | na | na | na | na | na | na | na |
| DI-13 | F | ET | 81 | 0 | 0 | BM smear | HU | M7 | 83 | 2 | complex, del(5q),−7 | 36 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-14 | F | ET | 75 | 0 | 0 | BM smear | HU | M2 | 77 | 2 | nd | 43 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| NA-08 | F | IMF | 62 | 0 | 0 | BM smear | HU/VP-16 | na | 69 | 7 | nd | 48 | PB smear | nd | 0 | PB smear | na | na | na | na | na | na | na | na | na |
| NA-09 | F | IMF | 62 | 0 | 0 | BM smear | Pipo/IFN | bi | 73 | 11 | nd | 38 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-20 | M | IMF | 65 | 0 | nd | BM smear | na | M7 | 67 | 2 | nd | 14 | BM smear | 0 | 0 | BMMC | na | na | na | na | na | na | na | na | na |
| p202 | M | IMF | 75 | nd | 0 | BM smear | HU | na | 80 | 5 | nd | 95 | PB smear | nd | 0 | PBMC | na | na | na | na | na | na | na | na | na |
| UPN . | Sex . | MPD . | AML . | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dx . | Age, y . | Nantes, %T . | Basel, %T . | Source . | Cytoreductive treatment . | Patient characteristics . | Unfractionated cell samples . | Purified cells . | |||||||||||||||||
| Granulocytic lineage . | Purified leukemic blasts . | T-cells . | |||||||||||||||||||||||
| FAB . | Age, y . | Delay, y . | Molecular and/or P cytogenetic abnormalities . | %Blasts . | source . | Nantes, %T . | Basel, %T . | source . | %T . | Source . | Method . | %T . | Source . | Method . | %T . | source . | Method . | ||||||||
| V617F-positive MPD/ V617F-negative AML | |||||||||||||||||||||||||
| NA-02 | F | PV | 70 | 79* | 94† | GRA/BM-CD15+ | Pipo | M2 | 72 | 2 | normal | 10 | BM smear | 0 | 0 | BMMC | 0 | PB-GRA | Ficoll | 0 | PB-CD34+ | FACS | 0 | PB-CD3+ | FACS |
| NA-32 | F | PV | 70 | 42 | 52 | PB GRA | Pipo | M1 | 72 | 2 | nd | 70 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| p128 | M | PV | 75 | nd | 30 | PB GRA | HU | M4 | 80 | 5 | Flt-3-ITD | 58 | PB smear | nd | 0 | PBMC | 0 | PB-CD15+ | MACS | 0 | PB-CD34+ | MACS | na | na | na |
| NA-01 | M | PV | 64 | 7 | 12 | BM smear | Pipo | M0 | 72 | 8 | nd | 91 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-03 | M | ET | 89 | 38 | 24 | PB GRA | HU | na | 91 | 2 | −Y | 42 | PB smear | 0 | 0 | PBMC | 0 | PB-GRA | Ficoll | 0 | PB-CD34+ | FACS | 0 | PB-CD3+ | FACS |
| BO-04 | F | ET | 52 | 21 | nd | PB GRA | None | M1 | 54 | 2 | t(10;16) | 93 | PB smear | 0 | 0 | PBMC | 0 | PB-GRA | Ficoll | na | na | na | na | na | na |
| DI-05 | M | ET | 69 | 12 | nd | BM smear | HU | M6 | 71 | 2 | complex, del(5q), +7, −Y | 52 | BM smear | 0 | 0 | BMMC | 0 | BM-CD15+ | FACS | 0 | BM-CD34+ | FACS | na | na | na |
| DI-35 | F | ET | 68 | 30 | 53 | BM smear | HU | M4 | 72 | 4 | complex, del(5q) | 45 | BM smear | 4 | 2 | BMMC | 0 | BM-CD15+ | FACS | 0 | PB/BM-CD34+ | FACS | 0 | PB/BM-CD3+ | FACS |
| NA-48 | M | IMF | 57 | 31 | 56 | BM smear | HU/Thal | M2 | 59 | 2 | complex, del(11q23) | 35 | BM smear | nd | 51 | BM smear | na | na | na | 0 | LC-blasts | LC | na | na | na |
| V617F-positive MPD/ V617F-positive AML | |||||||||||||||||||||||||
| NA-59 | M | PV | 64 | 46 | nd | PB GRA | HU/Pipo | na | 67 | 3 | nd | 15 | PB smear | 75 | nd | PBMC | 90 | PB-GRA | Ficoll | 85 | PB-CD34+ | FACS | 10 | PB-CD3+ | FACS |
| p185 | M | PV | 65 | nd | 30 | BM smear | HU | M2 | 83 | 18 | +8 | 75 | BM smear | nd | 69 | PB-CD34+ | 65 | PB-CD15+ | FACS | 69 | PB-CD34+ | FACS | na | na | na |
| NA-57 | F | ET | 47 | 82 | 89 | PB GRA‡ | HU | na | 60 | 13 | complex, del(20q), del(5q) | 15 | BM smear | 71 | 80 | PBMC | 78 | PB-GRA | Ficoll | 100 | PB-CD34+ | FACS | 0 | PB-CD3+ | FACS |
| DI-58 | F | ET | 64 | 26 | 34 | BM smear | na | M2 | 78 | 14 | complex, del(20q), −5, −7, +8 | 30 | BM smear | 41 | 66 | BMMC | 46 | PB-GRA | Ficoll | 56 | PB-CD34+ | FACS | 1 | PB-CD3+ | FACS |
| DI-60 | M | IMF | 71 | 75 | nd | BM smear | None | na | 74 | 3 | nd | 73 | PB smear | 80 | nd | PBMC | na | na | na | na | na | na | na | na | na |
| V617F-positive MPD/V617F-uninformative AML | |||||||||||||||||||||||||
| NA-30 | M | PV | 61 | 44 | nd | BM smear | 32P/Pipo | M2 | 68 | 7 | nd | 18 | BM smear | 43 | 67 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-33 | F | ET | 63 | 16 | nd | BM smear | HU/Pipo | M1 | 74 | 11 | nd | 91 | BM smear | 15 | nd | BM smear | na | na | na | na | na | na | na | na | na |
| NA-52 | M | IMF | 64 | 44 | 40 | BM smear | HU | M7 | 69 | 5 | nd | 24 | BM smear | nd | 59 | BM smear | na | na | na | na | na | na | na | na | na |
| V617F-negative MPD/V617F-negative AML | |||||||||||||||||||||||||
| NA-07 | M | PV | 53 | 0 | nd | BM smear | Pipo | M6 | 64 | 11 | nd | 75 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| NA-10 | M | ET | 67 | 0 | 0 | BM smear | HU | M4 | 74 | 7 | nd | 65 | PB smear | nd | 0 | PB smear | na | na | na | na | na | na | na | na | na |
| NA-11 | F | ET | 57 | 0 | 0 | BM smear | HU/32P/IFN/Ana | M2 | 73 | 16 | nd | 46 | PB smear | nd | 0 | PB smear | na | na | na | na | na | na | na | na | na |
| DI-12 | M | ET | 47 | 0 | nd | BM smear | HU | M7 | 49 | 2 | complex | 34 | BM smear | 0 | nd | BM smear | na | na | na | na | na | na | na | na | na |
| DI-13 | F | ET | 81 | 0 | 0 | BM smear | HU | M7 | 83 | 2 | complex, del(5q),−7 | 36 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-14 | F | ET | 75 | 0 | 0 | BM smear | HU | M2 | 77 | 2 | nd | 43 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| NA-08 | F | IMF | 62 | 0 | 0 | BM smear | HU/VP-16 | na | 69 | 7 | nd | 48 | PB smear | nd | 0 | PB smear | na | na | na | na | na | na | na | na | na |
| NA-09 | F | IMF | 62 | 0 | 0 | BM smear | Pipo/IFN | bi | 73 | 11 | nd | 38 | BM smear | 0 | 0 | BM smear | na | na | na | na | na | na | na | na | na |
| DI-20 | M | IMF | 65 | 0 | nd | BM smear | na | M7 | 67 | 2 | nd | 14 | BM smear | 0 | 0 | BMMC | na | na | na | na | na | na | na | na | na |
| p202 | M | IMF | 75 | nd | 0 | BM smear | HU | na | 80 | 5 | nd | 95 | PB smear | nd | 0 | PBMC | na | na | na | na | na | na | na | na | na |
UPN indicates unique patient number; M, male; F, female; Dx, diagnosis; nd, not done; na, not available; %T, percentage of chromosomes 9 carrying JAK2-V617F determined by AS-PCR; Nantes, AS-PCR was done in Nantes; Basel, AS-PCR was done in Basel; PB, peripheral blood; BM, bone marrow; GRA, granulocytes; PBMC, peripheral blood mononuclear cells; BMMC, bone marrow mononuclear cells; Pipo, pipobroman; HU, hydroxyurea; Thal, thalidomide; 32P, phosphorus 32; VP-16, etoposide; IFN, interferon-α; Ana, anagrelide; none, no cytoreductive treatment; FAB, AML diagnosis according to FAB classification; bi, biphenotypic leukemia; delay, interval between MPD and AML diagnosis in years; %Blasts, percentage of leukemic blasts on smear; LC-blasts, leukemic blasts isolated by laser capture microdissection.
%T determined in PB GRA.
%T determined in BM CD15+ cells.
Sample was taken 9 months before transformation to AML (not at MPD diagnosis), but no signs of AML were present in PB at this time.